UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

Clinical cancer research, 2019-04, Vol.25 (7), p.2174-2184

2019

Volltextzugriff (PDF)

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

Cancer immunology research, 2015-10, Vol.3 (10), p.1158-1164

2015

Volltextzugriff (PDF)

BRAF Mutations in Metanephric Adenoma of the Kidney

European urology, 2012-11, Vol.62 (5), p.917-922

2012

Volltextzugriff (PDF)

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma

Clinical cancer research, 2017-07, Vol.23 (14), p.3557-3565

2017

Volltextzugriff (PDF)

Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study

The lancet oncology, 2013, Vol.14 (1), p.81-87

2013

Volltextzugriff (PDF)

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

Journal of immunotherapy (1997), 2005-09, Vol.28 (5), p.488-495

2005

Volltextzugriff (PDF)

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)

Urologic oncology, 2013-11, Vol.31 (8), p.1788-1793

2013

Volltextzugriff (PDF)

Bevacizumab plus ipilimumab in patients with metastatic melanoma

Cancer immunology research, 2014-07, Vol.2 (7), p.632-642

2014

Volltextzugriff (PDF)

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

JAMA oncology, 2017-09, Vol.3 (9), p.1249

2017

Volltextzugriff (PDF)

Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805

Clinical cancer research, 2015-09, Vol.21 (18), p.4048-4054

2015

Volltextzugriff (PDF)

Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer

Clinical cancer research, 2007-04, Vol.13 (7), p.2100-2108

2007

Volltextzugriff (PDF)

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

Journal of translational medicine, 2009-07, Vol.7 (1), p.68-68, Article 68

2009

Volltextzugriff (PDF)

Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma

Clinical cancer research, 2020-11, Vol.26 (21), p.5598-5608

2020

Volltextzugriff (PDF)

Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings

Radiology, 2009-03, Vol.250 (3), p.793-802

2009

Volltextzugriff (PDF)

Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma

Radiology, 2021-02, Vol.298 (2), p.332-340

2021

Volltextzugriff (PDF)

Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma

Cancer, 2016-01, Vol.122 (1), p.124-130

2016

Volltextzugriff (PDF)

Multicenter phase ii trial of high-dose imatinib mesylate in metastatic melanoma : Significant toxicity with no clinical efficacy

Cancer, 2006-05, Vol.106 (9), p.2005-2011

2006

Volltextzugriff (PDF)

Age as a Prognostic Factor in Patients with Localized Melanoma and Regional Metastases

Annals of surgical oncology, 2013-11, Vol.20 (12), p.3961-3968

2013

Volltextzugriff (PDF)

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

Cancer, 2019-07, Vol.125 (14), p.2400-2408

2019

Volltextzugriff (PDF)

Angiopoietin 2 Is a Potential Mediator of High-Dose Interleukin 2–Induced Vascular Leak

Clinical cancer research, 2007-04, Vol.13 (7), p.2115-2120

2007

Volltextzugriff (PDF)

Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital

World journal of gastroenterology : WJG, 2015-04, Vol.21 (14), p.4373-4378

2015

Volltextzugriff (PDF)

Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer

Clinical cancer research, 2007-06, Vol.13 (11), p.3312-3319

2007

Volltextzugriff (PDF)

Long-Term Use of Nonsteroidal Anti-inflammatory Drugs Decreases the Risk of Cutaneous Melanoma: Results of a United States Case–Control Study

Journal of investigative dermatology, 2011-07, Vol.131 (7), p.1460-1468

2011

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Aktive Filter

KollektionAUTh Library subscriptions: Taylor & Francis Journals

Zeitschrift / SerieJournal Of Clinical Oncology

ThemaImmunotherapy

ThemaAged

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(80)

Sprache

Englisch
(80)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Humans
(80)
Male
(79)
Science & Technology
(79)
Life Sciences & Biomedicine
(78)
Middle Aged
(75)
Adult
(59)
Oncology
(43)
Aged, 80 And Over
(33)
Biological And Medical Sciences
(26)
Medical Sciences
(26)
Treatment Outcome
(24)
Carcinoma, Renal Cell - Drug Therapy
(20)
Kidney Neoplasms - Drug Therapy
(19)
Melanoma - Drug Therapy
(15)
Carcinoma, Renal Cell - Pathology
(14)
Kidney Neoplasms - Pathology
(14)
Neoplasm Staging
(14)
Dose-Response Relationship, Drug
(11)

13 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

BRAF Mutations in Metanephric Adenoma of the Kidney

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma

Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)

Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

Bevacizumab plus ipilimumab in patients with metastatic melanoma

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805

Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma

Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings

Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma

Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma

Multicenter phase ii trial of high-dose imatinib mesylate in metastatic melanoma : Significant toxicity with no clinical efficacy

Age as a Prognostic Factor in Patients with Localized Melanoma and Regional Metastases

Age as a Predictor of Sentinel Node Metastasis among Patients with Localized Melanoma: An Inverse Correlation of Melanoma Mortality and Incidence of Sentinel Node Metastasis Among Young and Old Patients

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

Angiopoietin 2 Is a Potential Mediator of High-Dose Interleukin 2–Induced Vascular Leak

Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital

Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer

Long-Term Use of Nonsteroidal Anti-inflammatory Drugs Decreases the Risk of Cutaneous Melanoma: Results of a United States Case–Control Study

Aktive Filter

Suchergebnisse filtern